Published in J Virol on June 01, 1989
Viral mutation rates. J Virol (2010) 3.87
Structure of a human rhinovirus complexed with its receptor molecule. Proc Natl Acad Sci U S A (1993) 3.62
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol (1995) 2.68
Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem (2005) 2.40
Role of maturation cleavage in infectivity of picornaviruses: activation of an infectosome. J Virol (1993) 2.39
Viral cell recognition and entry. Protein Sci (1994) 1.93
WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present. J Virol (1993) 1.66
Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J Virol (1994) 1.48
Poliovirus 2C region functions during encapsidation of viral RNA. J Virol (1997) 1.44
The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol (1995) 1.37
An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain. J Virol (1991) 1.31
WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14. J Virol (1993) 1.30
Acid-induced structural changes in human rhinovirus 14: possible role in uncoating. Proc Natl Acad Sci U S A (1992) 1.25
WIN 52035-dependent human rhinovirus 16: assembly deficiency caused by mutations near the canyon surface. J Virol (1998) 1.24
Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J Virol (1998) 1.23
Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds. J Virol (2004) 1.17
Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother (2005) 1.16
Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother (2004) 1.12
Closing the door on flaviviruses: entry as a target for antiviral drug design. Antiviral Res (2008) 1.09
Virus receptors: implications for pathogenesis and the design of antiviral agents. Clin Microbiol Rev (1995) 1.07
Human rhinovirus type 16: mutant V1210A requires capsid-binding drug for assembly of pentamers to form virions during morphogenesis. J Virol (2003) 1.07
Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J Virol (2009) 1.05
Interaction of decay-accelerating factor with echovirus 7. J Virol (2010) 0.98
Long-distance correlations of rhinovirus capsid dynamics contribute to uncoating and antiviral activity. Proc Natl Acad Sci U S A (2012) 0.96
Spectrum of activity of soluble intercellular adhesion molecule-1 against rhinovirus reference strains and field isolates. Antimicrob Agents Chemother (1994) 0.94
Discrimination among rhinovirus serotypes for a variant ICAM-1 receptor molecule. J Virol (2004) 0.93
Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14. Antimicrob Agents Chemother (1991) 0.93
Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host. Virology (2015) 0.91
Characterization of poliovirus variants selected for resistance to the antiviral compound V-073. Antimicrob Agents Chemother (2012) 0.91
Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus. Antimicrob Agents Chemother (2004) 0.90
Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother (1993) 0.89
Toward antiviral strategies that resist viral escape. Antimicrob Agents Chemother (2000) 0.87
Identification of viral mutants by mass spectrometry. Proc Natl Acad Sci U S A (1998) 0.87
In vitro selection of human rhinovirus relatively resistant to soluble intercellular adhesion molecule-1. Antimicrob Agents Chemother (1994) 0.87
Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J Virol (2000) 0.86
Mechanisms of viral mutation. Cell Mol Life Sci (2016) 0.85
Comparative sensitivity of the echovirus type 25 JV-4 prototype strain and two recent isolates to glutaraldehyde at low concentrations. Appl Environ Microbiol (1994) 0.81
A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis. PLoS Pathog (2017) 0.79
Potent antiviral agents fail to elicit genetically-stable resistance mutations in either enterovirus 71 or Coxsackievirus A16. Antiviral Res (2015) 0.77
Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses. ChemMedChem (2015) 0.76
Rapid evolution of RNA genomes. Science (1982) 14.76
Structure of a human common cold virus and functional relationship to other picornaviruses. Nature (1985) 12.90
On the structure of rhinovirus 1A. Virology (1971) 4.57
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40
The atomic structure of Mengo virus at 3.0 A resolution. Science (1987) 4.34
Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J Virol (1986) 4.15
Preponderance of synonymous changes as evidence for the neutral theory of molecular evolution. Nature (1977) 4.00
Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. J Virol (1986) 3.59
Evidence for at least two dominant neutralization antigens on human rhinovirus 14. J Virol (1985) 3.44
Evidence for the direct involvement of the rhinovirus canyon in receptor binding. Proc Natl Acad Sci U S A (1988) 3.29
Mitotic recombination in germ cells generated two major histocompatibility complex mutant genes shown to be identical by RNA sequence analysis: Kbm9 and Kbm6. Proc Natl Acad Sci U S A (1986) 3.15
Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother (1986) 2.70
Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J Virol (1989) 2.61
In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother (1985) 2.44
Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30
An inducible mammalian amber suppressor: propagation of a poliovirus mutant. Cell (1987) 2.08
Direct measurement of the poliovirus RNA polymerase error frequency in vitro. J Virol (1988) 1.99
Conservation of the putative receptor attachment site in picornaviruses. Virology (1988) 1.96
Influence of neighboring bases on DNA polymerase insertion and proofreading fidelity. J Biol Chem (1985) 1.78
Inhibition of poliovirus uncoating by disoxaril (WIN 51711). Virology (1987) 1.73
Antiviral agents targeted to interact with viral capsid proteins and a possible application to human immunodeficiency virus. Proc Natl Acad Sci U S A (1988) 1.22
Oral efficacy of WIN 51711 in mice infected with human poliovirus. Antimicrob Agents Chemother (1986) 1.18
Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice. J Infect Dis (1986) 1.05
Effect of base-pair stability of nearest-neighbor nucleotides on the fidelity of deoxyribonucleic acid synthesis. Biochemistry (1984) 0.94
Structure of a human common cold virus and functional relationship to other picornaviruses. Nature (1985) 12.90
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Observations on molecular weight determinations on polyacrylamide gel. J Biol Chem (1969) 7.60
Chemical and biological evolution of nucleotide-binding protein. Nature (1974) 7.39
X-ray crystallographic structure of the Norwalk virus capsid. Science (1999) 6.58
The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol (1980) 6.24
Systematic nomenclature of picornavirus proteins. J Virol (1984) 5.26
Structure of the bacteriophage phi29 DNA packaging motor. Nature (2000) 5.25
Comparison of super-secondary structures in proteins. J Mol Biol (1973) 4.85
Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
On the structure of rhinovirus 1A. Virology (1971) 4.57
Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J Gen Virol (1983) 4.45
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40
The atomic structure of Mengo virus at 3.0 A resolution. Science (1987) 4.34
Structure of Sindbis virus core protein reveals a chymotrypsin-like serine proteinase and the organization of the virion. Nature (1991) 4.24
Virus-specific proteins synthesized in encephalomyocarditis virus-infected HeLa cells. Proc Natl Acad Sci U S A (1971) 4.20
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol (2000) 4.01
Rotation function calculations with GLRF program. Methods Enzymol (1997) 3.99
Crystal structure of dimeric HIV-1 capsid protein. Nat Struct Biol (1996) 3.93
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Determining the intensity of Bragg reflections from oscillation photographs. Methods Enzymol (1985) 3.72
Protease required for processing picornaviral coat protein resides in the viral replicase gene. J Virol (1979) 3.70
Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66
Translation of encephalomyocarditis virus RNA in reticulocyte lysates: kinetic analysis of the formation of virion proteins and a protein required for processing. J Virol (1979) 3.64
Structure of a human rhinovirus complexed with its receptor molecule. Proc Natl Acad Sci U S A (1993) 3.62
Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. J Virol (1986) 3.59
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Properties of a ribonucleoprotein particle isolated from Nonidet P-40-treated Rous sarcoma virus. J Virol (1972) 3.25
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Telling the truth about terminal cancer. JAMA (1998) 3.07
Evidence for intramolecular self-cleavage of picornaviral replicase precursors. J Virol (1982) 3.03
Implications of the picornavirus capsid structure for polyprotein processing. Proc Natl Acad Sci U S A (1987) 2.99
Assembly of a tailed bacterial virus and its genome release studied in three dimensions. Cell (1998) 2.91
Preparation and characterization of encephalomyocarditis (EMC) virus. Methods Enzymol (1981) 2.81
Structural studies of avian myeloblastosis virus: comparison of polypeptides in virion and core component by dodecyl sulfate-polyacrylamide gel electrophoresis. J Virol (1974) 2.79
The structure of coxsackievirus B3 at 3.5 A resolution. Structure (1995) 2.73
Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71
Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother (1986) 2.70
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
Autonomous replication and expression of RNA 1 from black beetle virus. J Virol (1983) 2.68
Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol (1988) 2.67
The locked rotation function. Acta Crystallogr A (1990) 2.65
Synthesis of Black Beetle Virus Proteins in Cultured Drosophila Cells: Differential Expression of RNAs 1 and 2. J Virol (1981) 2.65
Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J Virol (1989) 2.61
Assembly-dependent maturation cleavage in provirions of a small icosahedral insect ribovirus. J Virol (1988) 2.60
Kinetics of synthesis and cleavage of encephalomyocarditis virus-specific proteins. Virology (1972) 2.54
Maturation cleavage required for infectivity of a nodavirus. J Virol (1992) 2.50
Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol (1989) 2.49
Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol (1997) 2.47
Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation (2001) 2.46
Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46
Identification of a protein binding site on the surface of the alphavirus nucleocapsid and its implication in virus assembly. Structure (1996) 2.46
In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother (1985) 2.44
Atomic structure of single-stranded DNA bacteriophage phi X174 and its functional implications. Nature (1992) 2.44
Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci U S A (2000) 2.42
Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol (1992) 2.42
Infection of mouse fibroblasts by cardioviruses: premature uncoating and its prevention by elevated pH and magnesium chloride. Virology (1971) 2.39
Role of maturation cleavage in infectivity of picornaviruses: activation of an infectosome. J Virol (1993) 2.39
Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol (1993) 2.39
A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1988) 2.38
Structure of beef liver catalase. J Mol Biol (1981) 2.35
Protein processing map of poliovirus. J Virol (1984) 2.33
Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30
Gene order of encephalomyocarditis virus as determined by studies with pactamycin. J Virol (1972) 2.26
Structural constraints of possible mechanisms of lactate dehydrogenase as shown by high resolution studies of the apoenzyme and a variety of enzyme complexes. Cold Spring Harb Symp Quant Biol (1972) 2.23
Structure of an insect virus at 3.0 A resolution. Proteins (1987) 2.23
Exploring structural homology of proteins. J Mol Biol (1976) 2.23
Protein folding. Annu Rev Biochem (1981) 2.21
Structural studies of two rhinovirus serotypes complexed with fragments of their cellular receptor. EMBO J (1999) 2.17
Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure (1998) 2.17
Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. Microb Pathog (2001) 2.15
Plaque assay for black beetle virus. J Virol (1984) 2.12
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08
A case-control study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1987) 2.07
Structure, sequence, and function correlations among parvoviruses. Virology (1993) 2.06
Structure and morphogenesis of bacteriophage T4. Cell Mol Life Sci (2003) 2.06
Studies of asymmetry in the three-dimensional structure of lobster D-glyceraldehyde-3-phosphate dehydrogenase. J Biol Chem (1975) 2.05
Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res (1992) 2.03
Pathogenesis of murine cytomegalovirus infection: the macrophage as a permissive cell for cytomegalovirus infection, replication and latency. J Gen Virol (1979) 2.01
Structure and assembly of large lipid-containing dsDNA viruses. Nat Struct Biol (2000) 2.00
Encephalopathy and fatty degeneratiof on the viscera in northeastern Thailand. Clinical syndrome and epidemiology. Pediatrics (1971) 2.00
Structure determination of feline panleukopenia virus empty particles. Proteins (1993) 1.99
Refined crystal structure of dogfish M4 apo-lactate dehydrogenase. J Mol Biol (1987) 1.98
The active center of catalase. J Mol Biol (1985) 1.97
The role of autolysins during vegetative growth of Bacillus subtilis 168. Microbiology (1998) 1.97
Black beetle virus: messenger for protein B is a subgenomic viral RNA. J Virol (1982) 1.96
Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat Struct Biol (2001) 1.91
Changes in three of the four coat proteins of oral polio vaccine strain derived from type 1 poliovirus. J Virol (1980) 1.91